Cargando…
Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a severe and progressive muscle wasting disorder, affecting one in 3500 to 5000 boys worldwide. The NO-sGC-cGMP pathway plays an important role in skeletal muscle function, primarily by improving blood flow and oxygen supply to the muscles during exercise. In fac...
Autores principales: | Krishnan, Shalini Murali, Nordlohne, Johannes, Dietz, Lisa, Vakalopoulos, Alexandros, Haning, Petra, Hartmann, Elke, Seifert, Roland, Hüser, Jörg, Mathar, Ilka, Sandner, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347633/ https://www.ncbi.nlm.nih.gov/pubmed/34360780 http://dx.doi.org/10.3390/ijms22158016 |
Ejemplares similares
-
The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms
por: Nelissen, Ellis, et al.
Publicado: (2022) -
Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
por: Becker-Pelster, Eva M., et al.
Publicado: (2022) -
The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats
por: Kraehling, Jan R., et al.
Publicado: (2023) -
sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension
por: Vogel, Julia, et al.
Publicado: (2021) -
Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
por: Cosyns, Sarah, et al.
Publicado: (2011)